Overview

12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa

Status:
Completed

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

A 12-week, multicenter, double-blind, randomized study designed to evaluate the safety and efficacy of 20 and 60 mg/day istradefylline compared with placebo in subjects with OFF-time phenomena and advanced Parkinson's disease treated with levodopa/carbidopa.

Phase:

Phase 2

Details

Lead Sponsor:

Kyowa Kirin Pharmaceutical Development, Inc.
Kyowa Kirin, Inc.

Treatments:

Istradefylline
Levodopa